Hypertensive left ventricular (LV) hypertrophy is associated with a substantial risk for malignant arrhythmias and sudden death. According to recent results, antihypertensive therapy with the angiotensin II type 1 receptor blocker irbesartan reverses both structural and electrical remodelling. However, the relation between the LV geometric pattern (concentric vs eccentric) and electrical reverse remodelling has not been characterized, neither has the relation between repolarization and rate (QT/RR and JT/RR relation), which presumably reflects the propensity for bradycardia-dependent ventricular arrhythmia. In this study, repeat echocardiographic and electrocardiographic measurements were performed in hypertensive patients with LV hypertrophy, randomized to double-blind therapy with irbesartan (n ¼ 44) or the b 1 -adrenoceptor blocker atenolol (n ¼ 48) for 48 weeks; 53 patients had concentric and 39 eccentric LV hypertrophy. In addition, 37 matched hypertensive subjects without LV hypertrophy and no current therapy served as controls. Irbesartan induced structural and electrophysiological reverse remodelling, independent of LV geometry. In contrast, atenolol had similar beneficial effect only in patients with concentric LV hypertrophy, while the response in those with eccentric hypertrophy was unfavourable with both prolonged repolarization time and an increased QT/RR slope (suggesting reverse-use dependence). In conclusion, there is a significant geometry-related difference in the reverse remodelling processes induced by irbesartan and atenolol. Echocardiographic characterization of the geometry in hypertension-induced LV hypertrophy might become an important step in the selection of optimal antihypertensive therapy.
Introduction
Hypertensive left ventricular (LV) hypertrophy is strongly associated with the occurrence of cardiovascular events, including myocardial infarction, congestive heart failure, ventricular arrhythmias and sudden death. 1, 2 Furthermore, a strong chain of evidence has been established for the mechanisms behind ventricular arrhythmias in myocardial hypertrophy 3, 4 and in heart failure, 5 based on which these conditions have been regarded as variants of, or predisposing to, the acquired long QT syndrome (LQTS). 6, 7 Thus, a relation has been established between prolongation and heterogeneity (dispersion) of repolarization on the one hand, and polymorphic ventricular arrhythmias, especially torsades de pointes ventricular tachycardia on the other hand. [3] [4] [5] [6] [7] [8] [9] Such arrhythmias are typically pause dependent, following sequences of short-long RR intervals. Consistent with these observations is the steeper relation between the QT and RR intervals (QT/RR relation) induced by drugs known to be proarrhythmic, 10, 11 and in LV hypertrophy (hypertrophic cardiomyopathy), 12 a phenomenon referred to as reverse-use dependence.
Antihypertensive therapy, especially blockade of the renin-angiotensin-aldosterone system, reduces LV mass. 13, 14 Reduction in LV mass in turn reduces the repolarization time and its dispersion, [15] [16] [17] the incidence and severity of ventricular arrhythmias 2 and the risk for cardiovascular events. 18, 19 We have recently shown that regression of LV mass induced by the angiotensin II type 1 receptor blocker (ARB) irbesartan rather than by the b 1 -selective adrenoceptor blocker atenolol is accompanied by improved repolarization. 16 There are, however, unsettled questions as to the effects of reverse remodelling by antihypertensive therapy. (1) How does it affect measures of depolarization and repolarization in concentric vs eccentric LV hypertrophy? (2) What are the effects on the relation between repolarization and rate (QT/RR and JT/RR relations), that presumably reflects the propensity for pause or bradycardia-dependent polymorphic arrhythmias? (3) Do antihypertensive drug classes have different effects in these aspects? These issues were addressed in the present analysis of the results from a double-blind study, where patients with hypertensive LV hypertrophy were randomized to receive irbesartan or atenolol in the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). 13 
Materials and methods

Study design
A total of 115 patients with hypertension and LV hypertrophy (by echocardiography) were included. 13 Exclusion criteria were known secondary hypertension, renal failure, LV dysfunction (here defined as an ejection fraction o45%), coronary or valvular heart disease, stroke and other serious concomitant diseases. No patient had a prior myocardial infarction or atrial fibrillation. In the present report 92 patients were included; 3 were excluded because of unsatisfactory echocardiographic recordings, 1 because a diagnosis of Conn's syndrome was made after completion of the trial and 19 patients due to missing or technically unsatisfactory electrocardiographic (ECG) recordings.
The study started with a 4-to 6-week single-blind placebo run-in period, after which patients with a seated diastolic blood pressure of 90-115 mm Hg were randomized to double-blind treatment with irbesartan (150 mg once daily) or atenolol (50 mg once daily). These doses were doubled after 6 weeks if required to reach a diastolic blood pressure o90 mm Hg. If diastolic blood pressure remained X90 mm Hg after 12 and 24 weeks, first hydrochlorothiazide and then felodipine were added. 13 Echocardiography and ECG recordings were performed at 0, 12 and 48 weeks. For comparison, 37 age-and gender-matched hypertensive patients without LV hypertrophy were examined once after 4-6 week of withdrawal of all antihypertensive treatment. The study was approved by the Ethics Committee of Karolinska Institutet, and of all other participating centres. All patients gave their written informed consent.
Echocardiography
Echocardiographic assessments were obtained as previously described. 13 The Penn convention was used for calculation of LV mass, which was corrected for body surface area (LV mass index). LV hypertrophy was defined as an LV mass index 4131 g/m 2 for men and 4100 g/m 2 for women. All analyses were made by two persons, who were blinded for patient identity and date for recording, and the mean values were used. The intra-and interobserver coefficients of variation were 1 and 12-15%, respectively. 13 The relative wall thickness was calculated as (interventricular septum þ posterior wall thickness)/LV end diastolic diameter, and was considered increased if 40.45. 20 On the basis of LV morphology, subjects were classified into concentric hypertrophy (LV hypertrophy and increased relative wall thickness), eccentric hypertrophy (LV hypertrophy and normal relative wall thickness), concentric remodelling (normal LV mass and increased relative wall thickness) and normal geometry (normal LV mass and normal relative wall thickness).
Electrocardiography A 12-lead standard ECG was recorded following 10-15 min of supine rest. Paper speed was 50 mm/s. To avoid inter-observer variability, one skilled person only (blinded for patient identity and date for the recording) performed all ECG measurements with a digitizing table (Calcomp 2000, Digitizer Products Division, Anaheim, CA, USA). For each lead the QRS and QT intervals were measured and either calculated as the mean of three measured cycles or from one averaged cycle, as described elsewhere. 16 In leads where the T wave could not be identified, that particular lead was excluded from further analysis. In 97% of all ECG recordings X10 leads were measured. The JT interval was calculated in each lead as the difference between the QT and QRS intervals. Correction for heart rate (QTc and JTc) was performed according to Bazett (QTc ¼ QT/ ORR, and JTc ¼ JT/ORR, with RR in second, but without using the unit).
Franz and co-workers, 21 using endocardial and epicardial monophasic action potential recordings in patients with and without LV hypertrophy, have validated the relation between invasively assessed dispersion of repolarization time and QT dispersion on 12-lead ECG. We therefore used this non-invasive method to reflect, if not truly represent, dispersion of repolarization in this study. QT and JT dispersion was defined as the difference between the maximum and minimum QT and JT value of all measurable leads in each ECG. The coefficients of variation of QRS, QT and JT measurements are low (3-4%) when the intervals are measured either in lead II or as the mean of X5 leads, 22 while it is approximately 10 times greater for QT and JT dispersion.
The QT/RR relation was assessed according to Savelieva and co-workers 12 with each patient being represented by one QT/RR pair.
Blood pressure
At all clinic visits, trough (2473 h after the last dose) seated blood pressures were measured using a mercury sphygmomanometer after at least 10 min of rest.
Statistical analyses
Data are presented as mean values7s.d. or s.e.m., or with 95% confidence intervals, as appropriate. To evaluate longitudinal changes in ECG measurements and heart rate for the two treatment groups, repeated measures analysis of variance was used. Analysis of variance, including terms for gender, age, additional therapy, and changes in LV mass, blood pressure, serum potassium and in RR interval, was used for comparison between the study groups. The relation between the QT and RR intervals, as defined by the regression line (QT ¼a*RR þ b), was constructed according to the least-squares, method, and the slope (a) was compared before and after treatment, as described previously. 12 All statistical tests were two-sided and carried out to a significance level (P) of 0.05. JMP, version 4.0 (SAS Institute Inc., Cary, NC, USA) was used for the statistical analyses.
Results
ECG measures in patients with and without cardiac hypertrophy Patient characteristics and ECG measures are shown in Tables 1 and 2 . The groups with and without LV hypertrophy were well matched in most relevant aspects other than LV mass. The QRS interval (reflecting depolarization) was similar in the two groups. The significant differences in the mean and maximum QT intervals between patients with and without LV hypertrophy were therefore due to a significant increase in both the mean and maximum JT interval (reflecting the major part of repolarization), which were prolonged significantly by 7-9%. QT and JT dispersion was 27-29% greater in LV hypertrophy patients (Po0.01 for both), but there was no significant difference in QRS dispersion.
With regard to LV geometry, QRS dispersion was 25% greater at baseline in patients with eccentric, as compared to those with concentric LV hypertrophy (Po0.05), while the maximum QRS duration was 110714 and 104710 ms, respectively (P ¼ 0.064). There were no significant geometry-related differences in repolarization measures at baseline. As shown in Figure 1 , there seemed to be a steeper relation (slope) between the QT/RR and JT/RR intervals in patients with LV hypertrophy, as compared to those with LV mass within the reference limits. However, there was no statistically significant difference, and there was no discernible difference between eccentric and concentric LV hypertrophy (Table 2, Figure 1 ).
Effects of antihypertensive therapy on ECG measures
As previously reported, blood pressure was similarly reduced in both groups at week 48, but LV mass index was significantly more reduced in the irbesartan group. 13 Following 48 weeks of irbesartanbased therapy, equal proportions (47%) of patients with concentric and eccentric LV hypertrophy obtained normal LV geometry, while the corresponding percentages were 29 and 35% in the atenolol group (irbesartan vs atenolol P ¼ 0.11). 13 In the present report with slightly reduced patient numbers similar results were obtained. As expected, heart rate decreased more in the atenolol group, by À6, À11 and À22% for baseline heart rates of o60, 60-70 and 470 beats/min, respectively. The corresponding numbers for irbesartan were þ 2, À4 and À10%, respectively. Initial serum sodium and Table 3 and in Figure 2 . These changes evolved gradually over 48 weeks, as reported previously. 16 There were no relations between changes in QT or JT dispersions and LV mass in either treatment group. 16 Measures of depolarization and repolarization showed similar directional changes in the irbesartan group, independent of LV geometry. In contrast, in the atenolol group there was a significant difference between patients with concentric and eccentric LV hypertrophy, also when corrected for age, gender and changes in heart rate. In concentric LV hypertrophy atenolol-based therapy-induced reverse electrophysiological remodelling similar to irbesartan, while in eccentric LV hypertrophy there was a deterioration from an electrophysiological point of view with atenolol ( Figure 3 ). In patients with eccentric LV hypertrophy the major effect was related to a prolongation of repolarization, although also depolarization time increased. A 'c' denotes values corrected for heart rate. Significant differences from week 0 to 48, and significant differences between groups are shown as *Po0.05, **Po0.01 and ***Po0.001. Results are adjusted for age, gender and change in heart rate by multivariate analysis of variance.
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Discussion
The main finding of this study is that irbesartanbased therapy resulted in a favourable structural and electrophysiological reverse remodelling in hypertension-induced LV hypertrophy, independent of LV geometric pattern. In contrast, atenolol induced a similarly beneficial electrophysiological reverse remodelling only in patients with concentric LV hypertrophy, while the response in patients with eccentric LV hypertrophy was the opposite, and potentially unfavourable. These drug-related differences in response were observed in conventional ECG measures like the QT (QTc) and JT (JTc) intervals, as well as in their dispersion, and the QT/RR relation. This is a novel observation with theoretical and practical implications, although the mechanism remains to be clarified. Concentric LV hypertrophy seems to be associated with more ischaemic cardiovascular events than eccentric LV hypertrophy, 24, 25 although the degree of hypertrophy might be more important than the geometry. 26 The greatest QRS duration, that is the longest ventricular activation time, which is a prognostically ominous sign in different patient groups, 5, 27 was observed among patients with eccentric LV hypertrophy. 16, 28 In addition, QRS dispersion was significantly greater in eccentric LV hypertrophy in this study. Indeed, Koren et al. 24 discussed a possible relation between concentric LV hypertrophy and increased propensity for vascular events on one side, and between eccentric LV hypertrophy and ventricular arrhythmias and sudden death on the other. 24 Myocardial hypertrophy and arrhythmogenesis Prolonged action potential duration is a salient feature in myocardial hypertrophy, independent of cause. 3, 4 This may lead to early after-depolarizations and triggered activity, and increased dispersion of repolarization may sustain the arrhythmia. In the hypertrophic myocardium myofibrillar disarray, heterogeneous gap junction distribution and fibrosis are additional potentially arrhythmogenic components, which would affect depolarization and its synchronization, contributing to a substrate for reentry. Irbesartan may interact favourably with several relevant mechanisms. First, animal studies have shown important arrhythmogenic effects of angiotensin II on the cardiac conduction system, which has a high density of angiotensin II type-1-receptors. Angiotensin II reduces intracellular resistance, decreases conduction velocity and shortens the refractory period in cardiac myocytes, 29, 30 which might facilitate arrhythmogenesis by decreasing the size of the tissue required for establishing electrical re-entry . Furthermore, locally Cardiac repolarization in hypertension K Malmqvist et al administrated angiotensin II in the heart causes increased dispersion of the action potentials, 30 which might enhance the sustenance of an arrhythmia. In addition, in a rat model of eccentric LV hypertrophy induced by aortic banding, ARB prevents the development of disorganized cell-to-cell connections. 31 Second, angiotensin II can facilitate noradrenaline release by activation of pre-junctional angiotensin II type 1-receptors. 32 Third, pathological fibrosis is a common finding in LV hypertrophy. The fibrosis is reduced by inhibition of the reninangiotensin-aldosterone system, 33, 34 that thereby may contribute to reduce the risk for malignant arrhythmias and sudden death. Also, regression of structural microvascular changes that causes an abnormal coronary vasodilator reserve 35 can probably contribute to reduced risk of arrhythmias related to ischaemia. Finally, in the present clinical setting of hypertension and eccentric LV hypertrophy animal data provide intriguing results, since not only stretch induced by increased afterload but also stretch induced by sudden increases in preload might provoke arrhythmias. 36 In summary, our results show that irbesartan has beneficial effects on ventricular repolarization and its synchronization, independent of LV geometry. Ventricular depolarization was also favourably affected by irbesartan, at least when compared to atenolol.
Reverse-use dependence: QT/RR slope
The reverse-use dependence pattern of response (that is, the longer the RR interval the longer the repolarization measured as QT or JT) is typical for class IA and III anti-arrhythmic drugs. 10, 11 These drug classes prolong repolarization and are known to carry a risk for torsades de pointes polymorphic ventricular tachycardias, the acquired LQTS. However, this pattern is typical also in the congenital LQTS, 37 and was recently found to be predictive of sudden death in post-myocardial infarction patients. 38 We examined the repolarization dynamicity by the QT/RR slope, as described by Savelieva et al. 12 The repolarization dynamicity is similar whether evaluated according to Savelieva et al., 12 by 24 h Holter monitoring, exercise testing or pacing, providing multiple QT/RR pairs from the same and/ or several subjects. Although there are considerable differences in the slope of the linear QT/RR model between subjects, there is, at least in healthy individuals, a relatively high within-subject stability. 39 In our study, the baseline slopes in LV hypertrophy were similar to what has been found in hypertrophic cardiomyopathy by Savelieva et al. 12 Each individual served as his/her own control, and the changes in the QT/RR slopes were consistent with the changes in QT (and JT). The effect of irbesartan was thus towards a normalization of the relation between repolarization and the RR interval (or heart rate), while the opposite was observed when atenolol was given to patients with eccentric LV hypertrophy (see Figure 3 ).
Atenolol and irbesartan affect heart rate differently, which might be a confounding factor in the evaluation of repolarization dynamicity. However, the different effects of atenolol (but not of irbesartan) on repolarization dynamicity in concentric and eccentric LV hypertrophy occurred despite similar alterations in heart rate in patients with concentric and eccentric LV geometry (À9 vs À7 beats per minute with atenolol, and À4 vs À4 beats per minute with irbesartan, respectively). Similar results for treatment effects were obtained when we evaluated the QT/ORR slopes, as proposed by Sadanaga and co-workers 10, 11 originally for multiple QTÀORR pairs from 24 h Holter recordings. Thus, the QT/ORR slopes for irbesartan at weeks 0 and 48 were 9.9 and 8.6 for concentric, and 14.0 and 10.7 for eccentric LV hypertrophy; and for atenolol 13.0 and 6.4 for concentric, and 9.1 and 12.7 for eccentric LV hypertrophy, respectively. Evidence from animals and humans 21, 40 support that the ECG measures of repolarization and its heterogeneity used in this study are indicators of propensity for ventricular arrhythmias. Of note, ventricular arrhythmias in LV hypertrophy show similarities with those in the acquired LQTS and are typically polymorphic (torsades de pointes), and sensitive to bradycardia. The major reason is that dispersion of repolarization is rate dependent in the acquired and congenital LQTS, in contrast to the normal heart. 40 Any negative chronotropic drug effect might therefore add risk. The notion that the overall effect of b-adrenoceptor blockers in patients with coronary heart disease and congestive heart failure is beneficial is well established. Eccentric LV remodelling is not uncommon in heart failure patients. However, heart failure patients are likely to have greater sympatho-adrenal activation than hypertensive patients, and therefore a higher heart rate. This might reduce the risk for bradycardia-related or pausedependent arrhythmias. Alternatively, sympathetic activity is such an important risk factor for cardiac death in heart failure patients, that the net effect of b-adrenoceptor blockers is beneficial. In the hypertensive patient, however, b-adrenoceptor blockers may not reduce morbidity and mortality in elderly hypertensive patients, 41 as also supported by recent reports. 42, 43 Thus, the prognostic implications, if any, of prolonged repolarization by b-adrenoceptor blockade in hypertensive patients with LV hypertrophy (in particular those with eccentric LV hypertrophy), are still unclear and need further investigation.
Future perspective
What are the clinical implications of the results presented from the SILVHIA 13, 16 and LIFE studies, 14, 44 comparing an ARB (irbesartan and losartan, respectively), with a b 1 -adrenoceptor blocker (atenolol)? So far, the effects of irbesartan and losartan are consistent and supportive. However, the LIFE study authors were cautious and called for confirmation of the results of their exploratory analysis. 44 So did the author of an accompanying commentary, who specifically suggested 'y a double-blind trial investigating the incidence of sudden cardiac death in diabetic patients with left ventricular hypertrophy randomised to losartan versus a beta blocker (such as propranolol, timolol, metoprolol or carvedilol) basically because these beta-adrenoceptor blockers have proven benefit in post myocardial infarction and/or heart failure patients'. 45 In addition, our results suggest that echocardiographic characterization of the LV geometry in hypertensive patients might become an important tool in the process of selecting an individually optimized antihypertensive therapy.
Limitations
This study is relatively small, which reduces the power to obtain statistically significant results in every aspect addressed in the study. The present data should be interpreted with some caution due to both conceptual and methodological concerns related to QT dispersion. Furthermore, it is by inference only that the effects of irbesartan in this study can be described as electrophysiologically beneficial, as the actual occurrence of malignant arrhythmias is difficult to study. This would require larger study populations, as malignant arrhythmias are relatively uncommon. However, the arrhythmogenic chain of evidence is strong, 2, [14] [15] [16] [17] [18] including the assessment of QT (QTc) dispersion in LV hypertrophy, and circumstantial clinical evidence are supportive. 44 What is known about this topic K Hypertension-induced left ventricular hypertrophy is associated with a substantial risk for malignant arrhythmias and sudden death. K Antihypertensive therapy with an angiotensin II type 1 receptor blocker can reverse both structural and electrical cardiac remodelling. K However, the relation between left ventricular geometric pattern (concentric vs eccentric) and electrical reverse remodelling has not been characterized, neither has the relation between repolarization and heart rate, which presumably reflects the propensity for bradycardia-dependant ventricular arrhythmia.
What this study adds K The angiotensin II type 1 receptor blocker irbesartan induced structural and electrophysiological reverse remodelling, independent of left ventricular geometric pattern. K In contrast, the b 1 -adrenoceptor blocker atenolol had similar beneficial effect only in patients with concentric left ventricular hypertrophy, while the response in those with eccentric hypertrophy was unfavourable from an electrophysiological point of view. K Thus, there is a significant geometry-related difference in the reverse remodelling processes between antihypertensive drug classes. Echocardiographic characterization of the geometry in hypertension-induced left ventricular hypertrophy might become an important step in the selection of optimal antihypertensive therapy.
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